Organization
Emad Ibrahim, MD, Inc.
1 abstract
Abstract
A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%.Org: University of Tennessee Medical Center, Mid Florida Cancer Centers, Clermont Oncology Center, Emad Ibrahim, MD, Inc., Desert Hematology Oncology Medical Group, Inc.,